Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 48.89% is in line with its 5-year average of 44.91%, near the high end of its 5-year range (33.46%–51.22%).
1.58% above its 12-month average of 48.13%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 45.51%.
GROSS MARGIN
48.89%
GROSS MARGIN AVG TTM
48.13%
GROSS MARGIN AVG 3Y
45.82%
GROSS MARGIN AVG 5Y
44.91%
GROSS MARGIN AVG 10Y
46.52%
GROSS MARGIN AVG 15Y
47.58%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.58%
CURRENT VS 3Y AVG
+6.70%
CURRENT VS 5Y AVG
+8.86%
CURRENT VS 10Y AVG
+5.11%
CURRENT VS 15Y AVG
+2.76%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.92%
median of 850 covered companies
CURRENT VS SECTOR MEDIAN
+19.46%
vs the sector median at left
Market Cap
$159.14M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
Market Cap
$155.32M
Gross Margin
49.12%
TTM Avg
60.40%
3Y Avg
67.38%
5Y Avg
70.83%
Market Cap
$160.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$154.72M
Gross Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$164.64M
Gross Margin
42.60%
TTM Avg
53.28%
3Y Avg
52.45%
5Y Avg
54.03%
Market Cap
$150.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-29.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inogen, Inc. (INGN) | $157.61M | 48.89% | 48.13% | 45.82% | 44.91% |
| PepGen Inc. (PEPG)vs › | $158.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | 63.55% | 56.95% | 54.72% | 65.55% |
| Neuronetics, Inc. (STIM)vs › | $155.32M | 49.12% | 60.40% | 67.38% | 70.83% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.27M | 0.00% | 0.00% | 0.00% | 16.67% |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | 85.91% | 84.21% | 85.09% | 82.87% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $154.72M | N/A | 0.00% | 0.00% | 0.00% |
| Quanterix Corporation (QTRX)vs › | $164.64M | 42.60% | 53.28% | 52.45% | 54.03% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | 0.00% | 0.00% | 0.00% | -29.98% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 63.30% | 63.88% | 62.53% | 60.65% |
Gross Margin
48.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 45.51% |
| 2026-03-31 | 49.08% |
| 2025-12-31 | 50.44% |
| 2025-09-30 | 50.82% |
| 2025-06-30 | 44.80% |
| 2025-03-31 | 44.21% |
| 2024-12-31 | 45.32% |
| 2024-09-30 | 46.54% |
| 2024-06-30 | 48.15% |
| 2024-03-31 | 44.05% |
| 2023-12-31 | 37.10% |
| 2023-09-30 | 40.21% |
| 2023-06-30 | 40.71% |
| 2023-03-31 | 42.59% |
| 2022-12-31 | 33.46% |
| 2022-09-30 | 40.61% |
| 2022-06-30 | 44.75% |
| 2022-03-31 | 43.55% |
| 2021-12-31 | 50.51% |
| 2021-09-30 | 51.22% |
| 2021-06-30 | 49.56% |
| 2021-03-31 | 45.87% |
| 2020-12-31 | 46.04% |
| 2020-09-30 | 44.41% |
| 2020-06-30 | 45.68% |
| 2020-03-31 | 43.36% |
| 2019-12-31 | 42.98% |
| 2019-09-30 | 47.20% |
| 2019-06-30 | 49.69% |
| 2019-03-31 | 49.23% |
| 2018-12-31 | 50.35% |
| 2018-09-30 | 51.23% |
| 2018-06-30 | 49.85% |
| 2018-03-31 | 47.72% |
| 2017-12-31 | 48.22% |
| 2017-09-30 | 48.05% |
| 2017-06-30 | 49.23% |
| 2017-03-31 | 49.04% |
| 2016-12-31 | 48.55% |
| 2016-09-30 | 46.17% |
| 2016-06-30 | 48.04% |
| 2016-03-31 | 49.50% |
| 2015-12-31 | 49.54% |
| 2015-09-30 | 47.51% |
| 2015-06-30 | 47.29% |
| 2015-03-31 | 47.47% |
| 2014-12-31 | 47.45% |
| 2014-09-30 | 49.84% |
| 2014-06-30 | 49.73% |
| 2014-03-31 | 50.51% |
| 2013-12-31 | 51.49% |
| 2013-09-30 | 48.75% |
| 2013-06-30 | 54.85% |
| 2013-03-31 | 51.55% |
| 2012-12-31 | 50.83% |
| 2012-09-30 | 49.40% |
